Legal (Details Textual)	3 Months Ended
	Mar. 31, 2016
Legal and U.S. Regulatory Proceedings Details [Line Items]
Loss Contingency, Settlement Agreement, Terms	On December 4, 2015, Galderma Laboratories, L.P. and Galderma S.A., collectively referred to as Galderma, filed a complaint in the United States District Court for the Northern District of Texas against the Company alleging infringement of United States Patent No. 6,106,848 based upon the Companys submission to the FDA of an ANDA seeking FDA approval to market clobetasol propionate lotion 0.05% before the expiration patent asserted in the complaint.